Wilmington-area lab expands services
SL Pharma Labs announced an expansion of its services to include quality control analytical and microbiological support for marketed pharmaceutical products.
“Global pharmaceutical companies are...
AstraZeneca completes $1.26 billion acquisition of Ardea
AstraZeneca has completed its $1.26 billion acquisition of San Diego-based drug development company, Ardea Biosciences, Inc. The merger was approved by Ardea’s stockholders.
Each outstanding...
AstraZeneca, Rigel sign deal for potential new treatment for chronic asthma
AstraZeneca and Rigel Pharmaceuticals Inc. Tuesday announced an agreement for the global development and commercialization for a drug now being investigated as a treatment...
Microsoft tablet computer aimed at taking on IPad – Bloomberg
Microsoft Corp. unveiled its own Windows-powered tablet computer called Surface, altering its strategy of focusing on software and relying on partners to make the...
Newark-based iBio makes progress on patent
The U.S. Patent Office has accepted a patent application for the iBio Inc. iBioModulator platform. The platform aims to improve the potency and effectiveness...
AstraZeneca among pharma companies seeking antibiotics answers
A growing worry in medicine is bugs’ increasing resistance to antibiotics. At AstraZeneca’s research centre near Boston, scientists toil to find new weapons. Machines...
DuPont opens new office building
DuPont last week opened a new five-story, 220,000 square foot office building at its Chestnut Run facility – incorporating sustainability into the building design...
SDIX reports loss, partnership with drug company
SDIX, a Glasgow, Del. provider of biotechnology-based products and services reported a loss for the quarter and a partnership with a drug company. Revenue...
DuPont acquires remainder of soy venture
DuPont, on May 1, took full ownership of St. Louis-based soy-based ingredients joint venture Solae. DuPont previously owned 72 percent of the joint venture...
WEEK IN REVIEW – A tale of 2 pharma companies, casino earnings perk up
Most businesspeople in Delaware know little about Incyte.
The pharmaceutical development company, based in DuPont research space at the Experimental Station has quietly built a...
Incyte posts loss as stock price stays around 52-week high
Drug developer Incyte Corp. is reporting revenue from a new product on the market, although the company's loss widened in the first quarter, due...
AstraZeneca $1.26 paying billion for developer of gout drug
AstraZeneca headquarters in London.
AstraZeneca is betting on the success of a promising drug used to treat gout in its merger deal for Ardea Biosciences,...
AstraZeneca, Bristol-Myers Squibb drug wins OK from European panel
AstraZeneca and Bristol-Myers Squibb Company reported a committee for a European Union agency has recommended the approval of FORXIGA tablets for the treatment of...
Biotech venture pairing researchers, companies under way
The Delaware Biotechnology Institute and the Delaware Economic Development Office announced eight research projects through the recently launched Delaware Bioscience Center for Advanced Technology...
iBio antibody shows promise
Newark-based IBIO announced that its iBioLaunch plant-based technology for the production of a copy of palivizumab, an antibody that fights a condition that strikes...
